A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Z-Butylidenephthalide (Primary) ; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Everfront Biotech
- 27 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Dec 2021.
- 27 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Dec 2020.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.